Pair page
N-Acetyl Semax with Selank
Mechanism-tag overlap and published literature for N-Acetyl Semax and Selank, pulled verbatim from each Kalios compound profile. Kalios is a literature reference, not a recommendation.
Mechanism overlap
Mechanism tags are verbatim labels on each compound's profile. Generic tags ("peptide", "small-molecule", "research-chemical") are excluded from this overlap view. Tags are descriptive — not an inference about combined effect.
4-7stabilized-acth-nootropic-analog
anxiolytic-nootropictuftsin-analog
Co-administration notes from the literature
Verbatim summary text pulled from each compound's profile data. Researchers studying N-Acetyl Semax and Selank have published these mechanism-level observations. Not a co-administration recommendation.
Parent (non-acetylated) Selank; same complementary logic with slightly different pharmacokinetics. Russian clinical literature has evaluated parent Semax + parent Selank extensively.
Quick facts
N-Acetyl Semax
Selank
Literature table
Classified references from each compound profile. Click a column header to sort. Click a PMID to open PubMed. Findings are quoted verbatim from each profile's literature_summary; nothing here is added or interpreted.
| Year | Compound | Source | Finding |
|---|---|---|---|
| 2011 | N-Acetyl Semax | Stavchansky VV, Yuzhakov VV, Botsina AY, Skvortsova VI, Bondurko LN, Tsyganova MG, Limborska SA, Myasoedov NF, Dergunova LV. The effect of Semax and its C-end peptide PGP on the morphology and proliferative activity of rat brain cells during experimental ischemia: a pilot study.… PMID 21409522 | human pilot |
| 2018 | N-Acetyl Semax | Gusev EI, Martynov MY, Kostenko EV, Petrova LV, Bobyreva SN. The efficacy of semax in the treatment of patients at different stages of ischemic stroke. Zh Nevrol Psikhiatr Im S S Korsakova. 2018;118(3. Vyp. 2):61-68. PMID: 29798983. PMID 29798983 | human study |
| 2014 | N-Acetyl Semax | Medvedeva EV, Dmitrieva VG, Povarova OV, Limborska SA, Skvortsova VI, Myasoedov NF, Dergunova LV. The peptide semax affects the expression of genes related to the immune and vascular systems in rat brain focal ischemia: genome-wide transcriptional analysis. BMC Genomics. 2014;15… PMID 25476978 | preclinical, in vivo |
| 2006 | N-Acetyl Semax | Dolotov OV, Karpenko EA, Inozemtseva LS, Seredenina TS, Levitskaya NG, Rozyczka J, Dubynina EV, Novosadova EV, Andreeva LA, Alfeeva LY, Kamensky AA, Grivennikov IA, Myasoedov NF, Engele J. Semax, an analog of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression… PMID 16996037 | preclinical, in vivo |
| 2001 | N-Acetyl Semax | Shadrina MI, Dolotov OV, Grivennikov IA, Slominsky PA, Andreeva LA, Inozemtseva LS, Limborska SA, Myasoedov NF. Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog. Neurosci Lett. 2001;308(2):115-118. PMID: 11457574. PMID 11457574 | preclinical, in vivo |
| 2023 | N-Acetyl Semax | Dergunova LV, Filippenkov IB, Limborska SA, Myasoedov NF. Neuroprotective Peptides and New Strategies for Ischemic Stroke Drug Discoveries. Genes (Basel). 2023;14(5):953. PMID: 37239312. PMID 37239312 | research article |
| 2005 | N-Acetyl Semax | Eremin KO, Kudrin VS, Saransaari P, Oja SS, Grivennikov IA, Myasoedov NF, Rayevsky KS. Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochem Res. 2005;30(12):1493-1500. PMID: 16362767. PMID 16362767 | research article |
| 2004 | N-Acetyl Semax | Levitskaya NG, Sebentsova EA, Andreeva LA, Alfeeva LY, Kamenskii AA, Myasoedov NF. Investigation of the spectrum of physiological activities of a heptapeptide analog of ACTH(4-10) — Semax. Neurosci Behav Physiol. 2004;34(4):399-405. PMID: 15341214. PMID 15341214 | research article |
| 2001 | N-Acetyl Semax | Kost NV, Sokolov OYu, Gabaeva MV, Grivennikov IA, Andreeva LA, Miasoedov NF, Zozulia AA. Semax and selank inhibit the enkephalin-degrading enzymes from human serum. Bioorg Khim. 2001;27(3):180-183. PMID: 11443939. PMID 11443939 | research article |
| 1997 | N-Acetyl Semax | Gusev EI, Skvortsova VI, Miasoedov NF, Nezavibat'ko VN, Zhuravleva EIu, Vanichkin AV. Effectiveness of semax in acute period of hemispheric ischemic stroke (a clinical and electrophysiological study). Zh Nevrol Psikhiatr Im S S Korsakova. 1997;97(6):26-34. PMID: 11517472. PMID 11517472 | research article |
| 1997 | N-Acetyl Semax | Ashmarin IP, Nezavibat'ko VN, Myasoedov NF, Kamenskii AA, Grivennikov IA, Ponomareva-Stepnaia MA, Andreeva LA, Kaplan AIa, Koshelev VB, Riasina TV. A nootropic adrenocorticotropin analog 4-10-semax (15 years experience in its design and study). Zh Vyssh Nerv Deiat Im I P Pavlova… PMID 9234274 | research article |
| 2008 | Selank | Zozulia AA, Neznamov GG, Syunyakov TS, et al. [Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48. PMID: 18454096. (Russian Phase… PMID 18454096 | human trial, Phase 3 |
| 2015 | Selank | Medvedev VE, Teresh'chenko OE, Israelyan AY, et al. [Optimization of therapy with traditional anxiolytic drugs in patients with anxiety-asthenic disorders]. Zh Nevrol Psikhiatr Im S S Korsakova. 2015;115(4):33-40. | human study |
| 2008 | Selank | Uchakina ON, Uchakin PN, Miasoedov NF, et al. [Immunomodulatory effects of selank in patients with anxiety-asthenic disorders]. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(5):71-75. | human study |
| 2019 | Selank | Inozemtseva LS, Kudryavtseva NN, Bobkova NV, Dolotov OV, Gerasimova OA, Levitskaya NG, Kamensky AA, Andreeva LA, Myasoedov NF, Grivennikov IA. Selank, Peptide Analogue of Tuftsin, Protects Against Ethanol-Induced Memory Impairment by Regulating of BDNF Content in the Hippocampus… PMID 31625062 | preclinical, in vivo |
| 2017 | Selank | Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Biomed Res Int. 2017;2017:2875904. PMC5322660. | preclinical, in vivo |
| 2008 | Selank | Inozemtseva LS, Karpenko EA, Dolotov OV, Levitskaya NG, Kamensky AA, Andreeva LA, Grivennikov IA. Intranasal administration of the peptide Selank regulates BDNF expression in the rat hippocampus in vivo. Dokl Biol Sci. 2008;421:241-243. PMID: 18841778. PMID 18841778 | preclinical, in vivo |
| 2007 | Selank | Semenova TP, Medvinskaia NI, Nesterova IV, Kozlovskaia MM. [Experimental analysis of the effect of Selank on the emotional and cognitive behavior of mice]. Zh Vyssh Nerv Deiat Im I P Pavlova. 2007;57(6):738-743. | preclinical, in vivo |
| 1998 | Selank | Seredenin SB, Kozlovskaia MM, Blednov IuA, Kozlovskii II. [Anxiolytic properties of Selank in BALB/c mice with differences in dopamine system reactivity]. Biull Eksp Biol Med. 1998;126(4):402-406. PMID: 9868709. PMID 9868709 | preclinical, in vivo |
| 2009 | Selank | Russian Federation State Register of Medicines. Selank — 0.15% intranasal solution. Approved 2009. | regulatory / registry |
| 2017 | Selank | Filatova E, Kasian A, Kolomin T, Rybalkina E, Alieva A, Andreeva L, Limborska S, Myasoedov N, Pavlova G, Slominsky P, Shadrina M. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Front Pharmacol. 2017;8:89. PMID… PMID 28316569 | research article |
| 2016 | Selank | Volkova A, Shadrina M, Kolomin T, Andreeva L, Limborska S, Myasoedov N, Slominsky P. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016;7:31. PMID: 26903861. PMC4757669. PMID 26903861 | research article |
| 2003 | Selank | Kozlovskaya MM, Kozlovskii II, Val'dman EA, Seredenin SB. Selank and short peptides of the tuftsin family in the regulation of adaptive behavior in stress. Neurosci Behav Physiol. 2003;33(7):639-643. PMID: 14552536. PMID 14552536 | research article |
Related pair pages
More research context
Frequently asked
Have N-Acetyl Semax and Selank been studied together?
Researchers have published mechanistic-level co-administration discussion of N-Acetyl Semax and Selank. No human co-administration trials are catalogued in the Kalios profiles. The pair page lists each compound's classified literature; full citations sit on each individual profile.
What mechanisms do N-Acetyl Semax and Selank share?
N-Acetyl Semax and Selank do not share a specific mechanism tag on their Kalios profiles. They appear on the same pair page because at least one profile lists the other in its co-administration data.
What is the FDA status of N-Acetyl Semax and Selank?
N-Acetyl Semax: Not listed. Selank: Not approved. FDA-status text is pulled verbatim from each compound profile. See /fda-pcac-2026.html for the broader FDA Pharmacy Compounding Advisory Committee context.
Where can I find the full research on N-Acetyl Semax and Selank?
Full citation lists, dosing tables from the literature, reconstitution data, and the FDA / WADA status are on the individual compound profiles: the N-Acetyl Semax profile and the Selank profile. The Kalios Stack Research Tool hub lists every compound covered.
Last updated: April 2026